SCHEMBL5145280

SCHEMBL5145280

COC(=O)c1ccc(-c2ccc(C(Cc3ccc(F)cc3)=C3NC(=O)NC3=O)o2)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
APEX1 P27695 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
APOBEC3A P31941 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPK1 P28482 2/20 0.40
PIK3CA P42336 1/20 0.38
PIK3CG P48736 1/20 0.38
LMNA P02545 2/20 0.38
PTPN7 P35236 1/20 0.36
PARP1 P09874 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 4/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
GAA P10253 1/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147466 0.77 MEN1 (0.44) KDM4EAPEX1TDP1APOBEC3ACTDSP1
SCHEMBL5145404 0.76 ENPP2 (0.43) KDM4EAPEX1TDP1MEN1KMT2A
SCHEMBL5145398 0.76 ENPP2 (0.43) KDM4EAPEX1TDP1MEN1KMT2A
SCHEMBL5145258 0.71 KDM4E (0.82) KDM4EAPEX1TDP1APOBEC3ACTDSP1
SCHEMBL5145265 0.71 KDM4E (0.82) KDM4EAPEX1TDP1APOBEC3ACTDSP1
SCHEMBL5146594 0.70 ALDH1A1 (0.55) KDM4EAPEX1TDP1CTDSP1MEN1
SCHEMBL5181927 0.68 SIRT2 (0.46) KDM4EMEN1KMT2AMAPK1LMNA
SCHEMBL14950619 0.64 TDP1 (0.53) KDM4ETDP1MEN1KMT2ALMNA
SCHEMBL14950616 0.64 TDP1 (0.53) KDM4ETDP1MEN1KMT2ALMNA
SCHEMBL16937873 0.64 TDP1 (0.57) KDM4ETDP1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KDM4E 4569/4885APEX1 2696/4885TDP1 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.